Laurence Anne Mevellec

This inventor holds 31 USPTO granted patents and 4 published patent applications, plus 15 CIPO patents and 19 EPO patents, primarily in Kinase Inhibitors. Top assignees: Janssen Pharmaceutica Nv, Astex Therapeutics Limited, Other. Active years: 2006-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Laurence Anne Mevellec. Retrieved from https://idiyas.com/inventor/laurence-anne-mevellec

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 31 (Patent Applications = 4)

% Patents Active = 71.0

CIPO Patents = 15 (Patent Applications = 9)

EPO Patents = 19 (Patent Applications = 21)

Average Co-Inventor Count = 5.4

ph-index = 7

Forward Citations = 135(Granted Patents)

Location History:

Issy-les-Moulineaux Cedex FR (2006)
Val de Reuil Cedex, FR (2015)
Louviers, FR (2007 - 2019)
Issy-les-Moulineaux, FR (2021)

Company Filing History:

26 out of 2,101

Janssen Pharmaceutica Nv

patents

4 out of 126

Astex Therapeutics Limited

patents

1 out of 834,570

Other

patents

Years Active: 2006-2026

Loading Chart...

Areas of Expertise:

CDK7 Inhibitors

HPK1 Inhibitors

PI3K Beta Inhibitors

PARP Inhibitors

Pyrazolyl Quinoxaline

Tetrahydrophenanthridinones

Farnesyl Transferase

Imidazopyridazine Derivatives

Quinazoline Derivatives

Tubulin Polymerization

Bicyclic Derivatives

Phthalazine Derivatives

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679839 - Cyclin-dependent kinase 7 (CDK7) non-covalent inhibitors (2026-07-14),

2. 12492194 - HPK1 inhibitors (2025-12-09),

3. 12486264 - Bicyclic HPK1 inhibitors (2025-12-02),

4. 10894793 - Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors (2021-01-19),

5. 10519137 - Pyrazolyl quinoxaline kinase inhibitors (2019-12-31),

6. 10342795 - Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors (2019-07-09),

7. 10280170 - Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors (2019-05-07),

8. 10202387 - Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors (2019-02-12),

9. 10087187 - Imidazopyridazine derivatives as PI3KB inhibitors (2018-10-02),

10. 9850228 - Pyrazolyl quinoxaline kinase inhibitors (2017-12-26),

11. 9598396 - Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors (2017-03-21),

12. 9464071 - Pyrazolyl quinoxaline kinase inhibitors (2016-10-11),

13. 9150540 - Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors (2015-10-06),

14. 8946221 - Phthalazine derivatives as PARP inhibitors (2015-02-03),

15. 8895601 - Pyrazolyl quinoxaline kinase inhibitors (2014-11-25),

Title: The Innovative Journey of Laurence Anne Mevellec: Pioneering Inventor from Louviers, FR

Introduction: Laurence Anne Mevellec is a renowned inventor hailing from the picturesque town of Louviers, France. With an impressive portfolio of 28 patents to his name, he has made groundbreaking contributions to the field of pharmaceuticals with his cutting-edge inventions.

Latest Patents: Mevellec's latest patents showcase his expertise in developing revolutionary compounds for medical applications. One such patent involves bicyclic pyridine, pyrazine, and pyrimidine derivatives that act as PI3K beta inhibitors, demonstrating his commitment to advancing treatment options in the healthcare industry. Another notable patent focuses on pyrazolyl quinoxaline kinase inhibitors, offering new possibilities in the realm of cancer treatment.

Career Highlights: Throughout his career, Mevellec has made significant strides in the pharmaceutical sector. He has lent his innovative prowess to esteemed companies such as Janssen Pharmaceutica Nv and Astex Therapeutics Limited, where his inventive spirit and dedication to scientific advancement have been instrumental in shaping the industry.

Collaborations: Mevellec has collaborated with accomplished peers in his field, including the likes of Patrick René Angibaud and Christophe Meyer. Together, they have worked on groundbreaking projects, further cementing Mevellec's reputation as a collaborative and forward-thinking inventor.

Conclusion: Laurence Anne Mevellec's journey as an inventor exemplifies a relentless pursuit of innovation and a steadfast commitment to creating solutions that have the potential to transform lives. His remarkable contributions continue to inspire and drive progress in the ever-evolving landscape of pharmaceutical research and development.

Profile summary based on public USPTO records.